THE CUTTING-EDGE SCIENCE TO TARGET CRUCIAL DRIVERS
OF INFLAMMATION AND CANCER
Our proprietary drug discovery and development engine has identified several immune drivers that have the ability to be “tuned up” or “tuned down” to modulate the immune system, either to suppress an overactive immune response in allergic inflammatory diseases or to initiate an immune response against cancer.
Our lead drug candidates, RPT193 and FLX475, target the important cell surface receptor CCR4 (C-C Motif Chemokine Receptor 4). Receptors such as CCR4 bind to chemoattractant molecules called chemokines that orchestrate migration and homing of cells to specific tissues throughout the body. Chemokines specific to CCR4 are secreted from allergically inflamed tissues and from tumors, but not from healthy tissues. Our proprietary approach is designed to prevent the recruitment of disease-promoting immune cells into inflamed tissues and tumors in order to treat allergic inflammatory diseases and cancer.